Intrinsic Therapeutics has enrolled the 400th patient in a level 1, prospective, randomized, multi-center clinical trial to evaluate the Barricaid Prosthesis for lumbar discectomy patients.
The study is being conducted in Germany, Switzerland, Austria and The Benelux to treat patients with sciatica. The project studies the safety and effectiveness of the Barricaid device and investigates clinical and radiographic information related to disc degeneration.
More Articles on Orthopedic and Spine Devices:
Lanx Publishes Favorable Study for ASPEN Minimally Invasive Spinal Fusion Device
Integra LifeSciences Receives FDA Clearance for Titan Reverse Shoulder System
DJO Global Posts $20.6M Net Loss in Q2